PTC-209

• GMP format available

PTC-209 is a potent and selective inhibitor of BMI-1 (B lymphoma Mo-MLV insertion region 1), with an IC50 value of 0.5 µM. This compound is widely used in cancer research due to its ability to target cancer-initiating cells (CICs) and reduce tumor growth.

Key features and applications include:

• Selective Inhibition: Specifically targets BMI-1, a key regulator in the self-renewal of cancer stem cells.
• Irreversible Action: Impairs the growth and self-renewal properties of colorectal cancer-initiating cells.
• High Potency: Demonstrates significant anti-cancer activity in various cancer cell lines including colorectal, breast, lung, and cervical cancer cells.
• Stem Cell Research: Investigates the role of BMI-1 in the self-renewal and proliferation of cancer stem cells.
• Combination Therapy: Explored in combination with other anticancer drugs to enhance therapeutic efficacy.

Relevant disease states include:

• Colorectal Cancer: Reduces tumor growth and the self-renewal capacity of colorectal cancer-initiating cells.
• Breast Cancer: Inhibits the proliferation of breast cancer cells and reduces tumorigenic potential.
• Lung Cancer: Decreases the viability and growth of lung cancer cells.
• Cervical Cancer: Promotes cell cycle arrest and apoptosis in cervical cancer cell lines.

PTC-209 is a valuable tool in the field of oncology, providing insights into the mechanisms of cancer stem cell self-renewal and offering potential therapeutic strategies for various cancers.